It is interesting that a recent real-life data study of 233 patients prospectively registered in the French alpelisib Early Access Program opened to PIK3CA-mutant, HR-positive, HER2-negative ABC patients treated with alpelisib and fulvestrant, showed that patients had received a median number of 4 prior systemic treatments for ABC, including CDK4/6 inhibitor (97.4%), chemotherapy (77.3%), or everolimus (56.2%), respectively. This evidence concerns the gene PIK3CA and aneurysmal bone cyst.